Share this article

UrgoStart in Real Life

Dr. Rajesh Kesavan, Dr. Prem Chand Gupta, Dr. Ravul Jindal, Dr. Belehalli Pavan, Dr. Venkateshwaran, Dr. Jessy Thomas, Dr. Bharat Kotru, Dr Sanjay Sharma, Dr. Pradeep Kumar, Dr. Selva SeethaRaman
29 April 2024

Chronic wounds are a challenge to clinicians involved in wound management and pose huge financial burdens on healthcare systems, while also having devastating effects on patients and their families.1 Chronic wounds are classified by aetiology, specifically, diabetic foot ulcers (DFUs), venous and arterial lower limb ulcers (LUs), and pressure injuries (PIs), as a consequence of the underlying diseases such as diabetes, peripheral arterial disease or chronic venous insufficiency.2 The cause of chronicity is the persistent inflammatory response created by common components within chronic wounds.3 

A 2005 community-based epidemiological study identified the prevalence of chronic wounds in India to be 4.5 per 1000 of the population, with lower extremity wounds being the most common.4 

Chronic wounds have been described as wounds that do not progress through a normal, orderly, and timely sequence of repair.5 Various publications try to estimate explicit timeframes of healing before a wound can be classified as longstanding chronic wounds, for instance 2 to 8 weeks for DFUs, and 4 weeks to 2 months for VLUs. Nonetheless a clear timeframe to define the chronicity of wounds and consensus on the timeline has never been provided or agreed upon.6,7 However, it is argued that such wounds may from the outset show chronic features, mainly due to excessive levels of matrix metalloproteinases (MMPs).7 The high levels of MMPs and decreased levels of tissue inhibitors (TIMPs) could be used as prognosis indicators, and, therefore, reducing the levels of the MMPs could optimise the healing outcomes of these challenging wounds.8  

The UrgoStart treatment range, (TLC-NOSF – Nano-oligosaccharide factor, sucrose octasulfate dressing based on technology lipido-colloid) was discussed in a recent systematic review9 where it has been concluded that these dressings ‘can provide clinicians with an evidence-based option for the management of chronic wounds which may be beneficial in  reducing  healing  times,  enhancing patients’ health related quality of life and providing economic benefits.’ The review identified a total of 21 publications of different levels, ranging from double-blind randomised control trials to case reports, involving over 12,000 patients (2021). 

The various publications draw attention to the greater benefits that are achieved when the UrgoStart treatment range is used as the first-choice treatment, as an integral part of the standard of care, to be initiated as soon as a patient presents to a clinician. Also, consistent benefits are achieved regardless of the characteristics of the wounds (such as wound aetiology, wound location, etc.) and provides a cost-effective solution that still offers the best healing outcomes in the management of chronic wounds, notwithstanding the age, size or location. There is a continuous growing recognition of the robustness of the evidence behind the UrgoStart treatment range amongst national authorities, payors and medical societies, as well as clinician endorsement, adoption and use of the UrgoStart treatment range for lower limb wounds, with these dressings being included in various guidelines and recommendations, including International Working Group on the Diabetic Foot (IWGDF 2019 & 2023)10, Diabetes Feet Australia (DFA)11, Vietnamese Association of Diabetes and Endocrinology (VADE)11, and the The National Institute for Health and Care Excellence of the UK (NICE 2019 & 2023).13 

In contact with wound exudate, the TLC-NOSF wound contact layer or healing matrix forms a gel that soaks up wound exudate and decreases levels of MMPs.14 The TLC-NOSF decreases MMP levels on the wound surface, promoting wound repair and shortening time to wound healing.13 It has also been shown that, when treating neuroischaemic DFUs with a TLC-NOSF dressing, transcutaneous oxygen pressure is improved.15

This document showcases the outcomes of the implementation of the UrgoStart treatment range, as part of a holistic standard of care, in a real-world environment, demonstrating positive outcomes of the management of chronic wounds in India with improvement in wound conditions and, furthermore, enhancing the patients’ quality of life and clinicians’ satisfaction. This study encompasses the experience of senior wound care clinicians from various specialities including Plastic Surgeons, Podiatrists, Vascular surgeons, and General surgeons. This real-world experience with the UrgoStart treatment range shows its effectiveness in healing a wide range of wounds.

Clinicians and healthcare systems need to ensure that the most effective, evidence-based wound management interventions are implemented for improved outcomes in individuals living with chronic wounds. 

Dr Rajesh Kesavan,
Director, Dr. RK Diabetic Foot and Podiatry Institute, & Rakesh Jhunjhunwala Amputation Prevention Centre; Adjunct Professor, Saveetha Medical College, Chennai, India

Disclaimer: This document has been developed by Wounds Asia and supported by an unrestricted educational grant from Urgo Medical.

1. Greener M. Independent Nurse. 2019;2019(10):12–15.

2. Frykberg RG, Banks J. Wound Care. 2015; 4(9):560–582.

3. Zhao R, et al. Int J Mol Sci. 2016; 17(12):2085.

4. Shukla VK, et al. Int J Low Extrem Wounds. 2005;4:7-8.

5. Bowers S, Franco E. American Family Physician. 2020;101:159-66.

6. Stacey M. Wounds Int. 2016;7:16–21.

7. Kyaw B, et al. Acta Derm Venereol. 2018;98:157–158.

8. Lazaro JL et al. J Wound Care. 2016;25:277–287.

9. Nair H, et al. J Wound Care. 2021;30:S42-S52.

10. Schaper NC, et al. Diabetes Metab Res Rev. 2020;36:e3266. Available from:

11. Diabetes Feet Australia. Australian Guidelines for diabetes-related foot disease. 2021. Available from: (Accessed February 2024).

12. Ministry of Health Medical Examination and Treatment Administration. Decision No. 1530/QD-BYT dated March 24, 2023 on the issuance of the professional document “Guidelines for diagnosis and treatment of diabetic foot ulcers”. Available from: (Accessed February 2024).

13. National Institute for Health and Care Excellence. UrgoStart for treating diabetic foot ulcers and leg ulcers. Medical technologies guidance. 2019. Available from: (Accessed February 2024).

14. White R, et al. Supporting evidence-based practice: a clinical review of TLC healing matrix. 2015. Available from: (Accessed February 2024).

15. Lázaro-Martínez JL, et al. Int J Low Extrem Wounds. 2022;21:450-456.

Free for all healthcare professionals

Sign up to the Wounds Group journals

By clicking ‘Subscribe’, you are agreeing that the Wounds Group are able to email you periodic newsletters. You may unsubscribe from these at any time. Your info is safe with us and we will never sell or trade your details. For information please review our privacy policy.

Are you a healthcare professional? This website is for healthcare professionals only. To continue, please confirm that you are a healthcare professional below.

We use cookies responsibly to ensure that we give you the best experience on our website. If you continue without changing your browser settings, we’ll assume that you are happy to receive all cookies on this website. Read about how we use cookies.

I am not a healthcare professional.